Adherence to the 2018 WCRF/AICR cancer prevention guidelines and chronic lymphocytic leukemia in the MCC-Spain study.


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
02 2020
Historique:
received: 06 08 2019
revised: 28 10 2019
accepted: 31 10 2019
pubmed: 23 11 2019
medline: 28 8 2020
entrez: 23 11 2019
Statut: ppublish

Résumé

Preventable risk factors for chronic lymphocytic leukemia (CLL) remain largely unknown. The aim of this study was to evaluate the association between adherence to nutrition-based guidelines for cancer prevention and CLL, in the MCC-Spain case-control study. A total of 318 CLL cases and 1293 population-based controls were included in the present study. The World Cancer Research Fund/American Institute for Cancer Research (WCRC/AICR) score based on the 2018 recommendations for cancer prevention (on body fatness, physical activity, and diet) was constructed. We used logistic regression analysis adjusting for potential confounders. Individuals in the highest tertile of the WCRF/AICR score had an odds ratio for CLL of 1.25 (95 % CI 0.91; 1.73) compared with individuals with low adherence (p-trend = 0.172). Each point increment in the score was associated with an OR for CLL of 1.06 (95 % CI 0.91; 1.23). Analyses by severity of disease did not show significant heterogeneity of effects. Overall, our results do not support an association between the WCRF/AICR score and CLL, yet we might have been limited by statistical power and study design to detect modest associations. Further research, ideally with a prospective design, long follow-up, and including additional lymphoma subtypes, is warranted to confirm the impact of composite healthy lifestyle behaviors on lymphoma risk.

Identifiants

pubmed: 31756676
pii: S1877-7821(19)30139-0
doi: 10.1016/j.canep.2019.101629
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101629

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Marta Solans (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, 17003, Girona, Spain; Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, 17004, Girona, Spain.

Dora Romaguera (D)

Balearic Islands Health Research Institute (IdISBa), University Hospital Son Espases, 07120, Palma de Mallorca, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain; ISGlobal, 08003, Barcelona, Spain.

Esther Gracia-Lavedan (E)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; ISGlobal, 08003, Barcelona, Spain; Universitat Pompeu Fabra (UPF), 08003, Barcelona, Spain.

Amaia Molinuevo (A)

Public Health Division of Gipuzkoa, BioDonostia Research Institute, 20014, San Sebastian, Spain.

Yolanda Benavente (Y)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908, Hospitalet De Llobregat, Spain.

Marc Saez (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, 17003, Girona, Spain.

Rafael Marcos-Gragera (R)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, 17003, Girona, Spain; Epidemiology Unit and Girona Cancer Registry, Catalan Institute of Oncology, 17004, Girona, Spain.

Laura Costas (L)

Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908, Hospitalet De Llobregat, Spain.

Claudia Robles (C)

Unit of information and interventions in infections and cancer (UNIC-I&I), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908, Hospitalet de Llobregat, Spain.

Esther Alonso (E)

Department of Patology, Hospital Universitari de Bellvitge, IDIBELL, 08907, L'Hospitalet de Llobregat, Spain.

Esmeralda de la Banda (E)

Department of Patology, Hospital Universitari de Bellvitge, IDIBELL, 08907, L'Hospitalet de Llobregat, Spain.

Eva Gonzalez-Barca (E)

Hematology, IDIBELL, Catalan Institute of Oncology, 08908, L'Hospitalet de Llobregat, Spain.

Javier Llorca (J)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Universidad de Cantabria - IDIVAL, 39011, Santander, Spain.

Marta Maria Rodriguez-Suarez (MM)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; IUOPA, University of Oviedo, ISPA-FINBA, 33003, Oviedo, Spain.

Macarena Lozano-Lorca (M)

Dpto. de Medicina Preventiva y Salud Pública. Universidad de Granada, 18071, Granada, Spain; Instituto de Investigación Biosanitaria de Granada.ibs, 18012, Granada, Spain.

Marta Aymerich (M)

Hematopathology Unit, Pathology Department, Hospital Clínic, University of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), 08008, Barcelona, Spain.

Elias Campo (E)

Hematopathology Unit, Pathology Department, Hospital Clínic, University of Barcelona, Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), 08008, Barcelona, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain.

Eva Gimeno-Vázquez (E)

Hematology Department, Hematology Department. Grup de Recerca Clínica Aplicada en Neoplàsies Hematològiques, Cancer Research Programme, IMIM-Hospital del Mar, 08003, Barcelona, Spain.

Gemma Castaño-Vinyals (G)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; ISGlobal, 08003, Barcelona, Spain; Universitat Pompeu Fabra (UPF), 08003, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain.

Nuria Aragonés (N)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Epidemiology Section, Public Health Division, Department of Health of Madrid, 28035, Madrid, Spain.

Marina Pollán (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Cancer Epidemiology Unit, National Centre for Epidemiology, Carlos III Institute of Health, 28029, Madrid, Spain.

Manolis Kogevinas (M)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; ISGlobal, 08003, Barcelona, Spain; Universitat Pompeu Fabra (UPF), 08003, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), 08003, Barcelona, Spain.

Silvia de Sanjose (S)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908, Hospitalet De Llobregat, Spain; PATH, Reproductive Health, Seattle, United States.

Pilar Amiano (P)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Public Health Division of Gipuzkoa, BioDonostia Research Institute, 20014, San Sebastian, Spain.

Delphine Casabonne (D)

Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain; Unit of Molecular and Genetic Epidemiology in Infections and Cancer (UNIC-Molecular), Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908, Hospitalet De Llobregat, Spain. Electronic address: dcasabonne@iconcologia.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH